PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma
Mariana Muniz da Paz(Universidade Federal do Rio de Janeiro), Luciana P. Rangel(Universidade Federal do Rio de Janeiro), Beatriz I. S. Ferreira(Fundação Oswaldo Cruz), Giulia D. S. Ferretti(Medical University of South Carolina), Jerson L. Silva(Universidade Federal do Rio de Janeiro), Otacílio C. Moreira(Fundação Oswaldo Cruz), Yraima Cordeiro(Universidade Federal do Rio de Janeiro), Thibaut Barnoud(Medical University of South Carolina), Mafalda M. C. Martins-Dinis(Universidade Federal do Rio de Janeiro), Amanda Faier-Pereira(Fundação Oswaldo Cruz)
Cited by 13
Related Papers
Ligand Binding and Hydration in Protein Misfolding: Insights from Studies of Prion and p53 Tumor Suppressor Proteins
|Accounts of Chemical Research|2009|110
Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands
|Chemical Science|2021|108
p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells
|Journal of Biological Chemistry|2019|86
Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers
|iScience|2020|82
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
|Chemical Reviews|2023|78